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Objective: The aim of this study was to determine in intact and inﬂamed knee joints of the rat, the effect
of the bradykinin (BK) B2 receptor antagonist fasitibant (MEN16132) on nociceptor mechanosensitivity
and hyperalgesia.
Methods: Joint afferent sensory ﬁbers of the medial articular nerve of anesthetized animals were elec-
trophysiologically recorded, measuring nerve impulse activity evoked by passive innocuous and noxious
movements of the joint, in intact and kaolin and carrageenan-injected joints. Knee joints of rats were also
acutely inﬂamed by intra-articular injection of carrageenan alone. Long term duration of fasitibant
antinociceptive effects were behaviorally evaluated using the incapacitance test.
Results: BK (100 mM) injected into the saphenous artery, induced excitation and sensitization of multi-
and single unit recordings. Fasitibant (300 mM) injected prior to BK, reduced its excitatory effects as well
as the overall increase of movement-evoked activity resulting from repeated injections of BK. Fasitibant
did not affect movement-evoked activity of sensory ﬁbers of intact, non-inﬂamed knee joints.
Intra-articular fasitibant (100 mg/knee) signiﬁcantly reduced the carrageenan-induced inﬂammatory
hyperalgesia measured with the incapacitance test up to four days after treatment. This antinociceptive
effect was not obtained with systemic endovenous injection of the drug.
Conclusions: Fasitibant prevents B2 receptor-mediated activation and sensitization of peripheral joint
afferents and the ensuing inﬂammatory hyperalgesia, and may be a useful, novel drug for arthritis pain
treatment.
 2013 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Bradykinin (BK) is a small peptide (Arg-Pro-Pro-Gly-Phe-Ser-
Pro-Phe-Arg) produced by proteolytic kallikreins following tissue
damage1. Its contribution to pain and inﬂammation has been
extensively analyzed in several experimental models2,3. Two kinin
receptors, belonging to the rhodopsin family of G protein-coupled
receptors, have been described: the inducible B1 receptor and the
constitutive B2 receptor. BK possesses a 10,000-fold higher afﬁnity
for the B2 receptor as compared with the B1, which is instead
preferably activated by kinin metabolites lacking of the C-terminalS. Meini, Menarini Ricerche
12A, 50131 Florence, Italy.
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s Research Society International. Parginine residue4. Once bound to B2 receptors, BK induces phos-
pholipase C (PLC) activation, ensuing a cascade of secondary events
that include protein kinase C (PKC) and phospholipase A2 phos-
phorylation, nitric oxide synthase activation, and subsequent
intracellular downstream signaling4,5. Different mechanisms
mainly linked to PLC and PKC activation, can account for the algo-
genic action of BK, characterized by sensitization and/or direct
activation of nociceptive afferent nerve terminals. BK-mediated
activation of different transducing ion channels such as transient
receptor potential channels (TRP) TRPV1, TRPV4 and TRPA1 has
been reported in polymodal nociceptors6e9. Also, BK inhibition of
M-type Kþ currents and simultaneous opening of Ca2þ-activated
Cl channels have been reported10.
Osteoarthritis (OA) is a multifactorial disease and the involve-
ment of an inﬂammatory component, which is marked by symp-
toms such as joint pain, swelling and stiffness, is now well
recognized11,12. Carrageenan-induced experimental inﬂammation
model, besides to be used to investigate different mechanismsublished by Elsevier Ltd. All rights reserved.
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kinin receptors to the development of peripheral inﬂammatory
signs, such as increased vascular permeability, endothelial cell
proliferation and hyperalgesia15e19. As a conﬁrm, it has been shown
that carrageenan injection in mice deﬁcient of B2 receptor does not
cause nociception20. It has been also reported that ongoing and
movement-evoked impulse activity in afferent nociceptive nerve
ﬁbers of rat knee joints inﬂamed through intra-articular injection of
carrageenan, are augmented21e23 thus providing the electrophysi-
ological correlate of carrageenan-induced hyperalgesia. However,
the contribution of BK receptors to this enhanced joint nociceptor
activity has not been explored so far.
Intra-articular injection of icatibant, a metabolically resistant
peptide and selective B2 receptor antagonist currently used for the
therapy of hereditary angioedema attacks, has been shown to
reduce pain intensity at rest and during activity in patients with
symptomatic OA24. This speaks in favor of a contribution of B2
receptor activation to the augmented nerve impulse activity at
nociceptive ﬁbers during joint inﬂammation and opens the possi-
bility of using BK antagonists as new drugs for the treatment of
arthritic pain.
Fasitibant (previously known as MEN16132) is a nonpeptide
compound endowed with high afﬁnity and selectivity for the kinin
B2 receptor, and appears tobemorepotent than icatibant in blocking
BK effects mediated through B2 receptors in several in vitro and
in vivo models25e30. Moreover fasitibant is capable to block the
hyperalgesia experimentally induced by intra-articular knee joint
injection of monosodium iodoacetate in rats, as a model of
chemically-evoked degenerative OA31, as well as to partially inhibit
both the hyperalgesia and the inﬂammatory effects produced by the
intra-articular administration of carrageenan as a model of rat in-
ﬂammatory arthritis32,33. Fasitibant is currently under clinical
development and evaluated as symptomatic intra-articular treat-
ment of knee OA (clinical trial NCT01091116 registered).
As nociceptive ﬁbers are considered the fundamental source of
pain in knee OA34 the aim of the present investigation was to
evaluate the attenuating effect of fasitibant on BK-induced sensory
nerve activation by recording nociceptive activity of medial artic-
ular nerve ﬁbers in inﬂamed vs non-inﬂamed knee joints in rats,
and to explore the duration of its local antinociceptive effect on
inﬂamed joints, using behavioral techniques.Fig. 1. Nerve impulse activity recorded from primary afferent multiunits innervating
an inﬂamed knee joint. (AeB) Recordings of evoked impulses are displayed as
instantaneous frequency (top panel) and as the original nerve impulse recordingsMaterial and methods
Animals
Male adult rats (Harlan Laboratories, Udine, Italy) were housed
singly in cages in sanitary ventilated animal rooms with controlled
temperature (20C), humidity (45%) and maintained on ad libitum
food and water with a 12 h light/dark cycles. Procedures were
performed in accordance to the protocols approved by the Com-
mittee on Animal Research at the University Miguel Hernández, the
ethical committee of Menarini Ricerche and according to the
Spanish, Italian and European Union regulations (2010/63/UE).(lower panel). A correspond to the movement performed before BK injection and B
shows the increase activity after BK injection. (C) Outline of the experimental protocol.
The tibia was rotated against the femur with the time course and the torque in mNm,
shown in the axis. The outward rotations in two steps of 10 s each were followed by a
pause of 10 s and then by two corresponding inward rotations of the same duration.
OR, non-noxious outward rotation in the normal working range of the joint; NOR,
noxious outward rotation over the normal working range of the joint; IR, non-noxious
inward rotation; NIR, noxious inward rotation. (D) Diagram of the data analysis.
Movements along the experiments are represented by circles. Baseline: movements
used to calculate control values. Mean response: movements used to average the long-
term effects of the injected substances. White circles represent the activity evoked by
the ﬁrst movement after BK injection and it is called “immediate response”. The
average of the four white circles gives the “mean of the immediate responses” value.Recordings experiments
Experiments were performed in 42 Wistar rats (mean body
weight: 331  4 g) as previously described21,22,35.
Animals were initially anesthetized with ketamine (75 mg/kg)
and xylazine (10 mg/kg) (i.p.) followed by injection of 40 mg/kg
(i.p.) of sodium pentobarbital for deep anesthesia. Supplementary
doses of the anesthetic were injected through a venous catheter
when required. Body temperature and CO2 levels were kept atphysiological levels. Heart frequency and blood pressure values
were continuously monitored to evaluate the anesthesia level.
Surgery and inﬂammation were performed according to the
procedures described previously21,22,35 and are detailed in the
Supplementary Material.
Identiﬁcation and recording of knee joint afferent units
Brieﬂy, the saphenous nerve was cut both proximally to the
joint, in the inguinal region and distally from the joint. The prox-
imal end of the saphenous nerve was placed on a black platform
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Fig. 2. Movement-evoked activity recorded from primary afferent multiunits and single ﬁbers innervating an inﬂamed knee joint. Representative experiments showing the effects
of BK (A (n ¼ 5), B (n ¼ 4)) and fasitibant plus BK (C (n ¼ 4), D (n ¼ 5)). Circle symbols in the graphs represent the averaged response of impulse activity evoked by non-noxious and
noxious outward and inward rotations. The red arrows indicate the interval between movements at which the substances are injected. The red dots indicate the movement used for
the activity analysis. Dotted lines indicate control baseline.
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electrode for extracellular recording.
The sensitivity to knee joint movements of articular afferent
units was explored using the protocol shown in panel C ofBA
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Fig. 3. Effect of BK and fasitibant on the movement-evoked impulse activity of ﬁne primar
multi and single units innervating inﬂamed knee joints (AeC) and non-inﬂamed joints (D)
formed prior the injections. These values were set to 100% and considered as control respo
group i.e., multiunits (n ¼ 5) and single ﬁbers (n ¼ 4) recorded from animals receiving inject
animals receiving injections of fasitibant and BK (purple dots) (AeC), multiunits (n ¼ 5) and
blue dots respectively) (D) and single ﬁbers (n ¼ 4) recorded from animals receiving injecti
represent 95% CI. *P < 0.05, **P < 0.01, ***P < 0.001 denote statistical signiﬁcance betweenFigs. 1 and 4. The maneuver started from a resting, middle position
of the joint and consisted of a 10 s outward rotation within the
working range of the joint (non-noxious) continued by a 10 s
duration outward rotation which overpasses the normal working-40
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y afferences. Dot plots summarizing the nerve activity recorded from primary afferent
. Black dots in ﬁgures A and D represent the averaged activity of the movements per-
nses. The color dots represent data from individual experiments in each experimental
ions of BK (green dots) (AeC), multiunits (n ¼ 4) and single ﬁbers (n ¼ 5) recorded from
single ﬁbers (n ¼ 5) recorded from animals receiving injections of fasitibant (red and
ons of saline (blue dots) (D). Horizontal bars represent the mean values and error bars
treatments.
Fig. 4. Nerve impulse activity recorded from primary afferent multiunits innervating
an inﬂamed knee joint. (AeB) Recordings of evoked impulses are displayed as
instantaneous frequency (top panel) and as the original nerve impulse recordings
(lower panel). A, correspond to the movement performed before substances injection
and B shows the activity after injection of 200 ml of fasitibant 300 mM, followed by the
injection of 200 ml of BK 100 mM 30 s afterward. (C) Shows an outline of the experi-
mental protocol [for details see Fig. 1(C)].
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the resting position for 10 s and the same maneuvers were per-
formed using inward rotations21,22,35,36. The discharges recorded
during the complete movement cycle, were analyzed by counting
the total number of impulses evoked by the four rotations
[ORþNORþ IRþNIR; represented by circles in Fig.1(D)]. After four
movements, a 200 ml intra-arterial injection of BK 100 mM, fasiti-
bant 300 mM, of both substances or saline was performed and the
effect assessed in next movement following the injection [white
circles, Fig. 1(D)]. The injection of the test substance was repeated
up to ﬁve times at 30e35 min intervals. Movement cycles were
repeated every 5 min.
Experimental groups in recording experiments
The animals were divided in four groups. Animals that received
intra-arterial injections of BK alone (group 1); animals receiving
injections of fasitibant 30 s previous to the injection of BK
(group 2); animals receiving injections of fasitibant alone (group 3),
and animals receiving injections of saline (group 4).
Analysis of data
The numbers of impulses/cycle evoked by the four movement
cycles, preceding the ﬁrst injection of the test substance wereaveraged. This valuewas taken as the “control response” and served
as 100%. Accordingly, the number of impulses during the move-
ment cycles performed along the post-injection period was
expressed as percentage of the control response.
The numbers of impulses of all movement cycles of the post-
injection period were averaged and this value was called “mean
response” and served to evaluate the overall sensitization to
repeated injections of BK and its modiﬁcation by fasitibant
[Fig. 1(D)].
We called “immediate response” of BK the activity evoked by the
ﬁrst movement that followed the injection of the drug [ﬁrst white
circle in Fig. 1(D)]. The values of all the immediate responses
evoked by repeated injections of BK were also averaged to obtain a
“mean value of the immediate response” in each experiment
[Fig. 1(D)].
Behavioral experiments
Experiments were performed in 42 Wistar rats (250e300 g) as
previously described28. Inﬂammationwas induced in the right knee
joint by intra-articular injection (25 ml) of 2% l-carrageenan
whereas an equal volume of sterile saline was administered in the
left knee joint. Animals belonging to the control group were intra-
articularly administered with saline.
Experimental groups in behavioral experiments
Animals were randomized into six experimental groups. Ani-
mals that received intra-articular saline (group 1, n ¼ 6, control);
animals that received intra-articular carrageenan (group 2, n ¼ 12);
animals receiving intra-articularly different doses (10, 30,100 mg) of
fasitibant 30 min previous carrageenan treatment (group 3, 4, 5,
n ¼ 6 each); animals receiving intravenously 100 mg of fasitibant
30 min previous carrageenan treatment (group 6, n ¼ 6).
Treatment and weight bearing measurements
Fasitibant intravenous administration was performed in the tail
vein (0.3 ml). Intra-articular injection (25 ml) was made into the
right knee joint of anaesthetized rats (pentobarbital, 40 mg kg1
i.p.), that received 25 ml of sterile saline into the contralateral (left)
knee. The antagonist was administered 30min before the induction
of inﬂammation. After each intra-articular injection37, the knee
joint was repeatedly ﬂexed and extended to allow the dispersion of
both drugs and carrageenan. The animals recovered from anes-
thesia within 60e90 min.
Pain related to knee joint inﬂammation was assessed by an
incapacitance tester MkV (Linton Instrumentation, Norfolk, UK) to
measure carrageenan-treated (right) and saline-treated (left) limb
weight distribution. Rats were placed in an angled plexiglass
chamber positioned so that each hind paw rested on a horizontal
force-transducing plate. The weight (g) borne by each hind limb
was averaged over 5 s; eight readings were taken and mean values
calculated. Animals hind limb weight bearing behavior was
measured on the same animals repeatedly over the course of the
study. Results are right hind limbweight bearing as a percentage of
total weight borne by both hind limbs (no change around 50%).
Statistical analysis
In nerve recording experiments, statistical comparisons were
generated using SigmaStat (Systat Software, Inc., CA). We used the
paired t-test to compare changes in the animals before and after
treatments and the Student’s t-test for comparison between ani-
mals groups, as indicated.
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using GraphPad Prism 4.0 (San Diego, CA). Raw data were analyzed
by the one-way analysis of variance (ANOVA) followed by Dunnett’s
multiple comparison test. The percentage of antinociceptive effect
was calculated against the value obtained in the carrageenan group.
Data are reported as mean and 95% conﬁdence interval (CI) in
parentheses. The signiﬁcance level was set at P < 0.05.
Drugs
Fasitibant (chloride dihydrochloride salt, batch number 42758P,
Menarini Ricerche, Chemistry Development Department, Pisa,
Italy)25.
Fasitibant was dissolved in saline and sterilized by ﬁltration
(MillexGV 0.22 mm, Millipore, Billerica, MA). l-carrageenan, kaolin
and BK were from SigmaeAldrich (St. Louis, MO).
Results
Electrophysiological recordings
Successful recordings of duration longer than 120 min were
obtained from 35 nerve ﬁlaments of the saphenous nerve of
separate animals (one ﬁlament per animal, n ¼ 35). 21 recordings
correspond to ﬁlaments containing a single active unit and 14 to
ﬁlaments exhibiting multiunit activity. Most of the saphenous
nerve ﬁbers of rats responding to movements of the knee joint had
conduction velocities (CV) that included them either into the thin
myelinated, A-delta group (CV ¼ 2.5e20 m/s) or in the unmyelin-
ated C-ﬁber group (CV2.5 m/s; Table I).
Effect of BK on joint nerve activity
As shown in the example of a multiunit recording illustrated in
Fig. 1, joint movements of the inﬂamed joint in the working range
(non-noxious OR and IR) did not generate impulse activity or at best
evoked a very low ﬁring response; however rotations that exceeded
the working range of the joint (noxious rotation, NOR, NIR) yield a
vigorous ﬁring response in all phases of the cycle [Fig. 1(A)]. After
BK injection, movements of the joint in the working range (OR
movement) already evoked a burst of impulses, and impulse
activity during noxious rotations was considerably increased, i.e.,
the units became sensitized [Fig. 1(B)].
Repeated intra-arterial injection of 200 ml BK 100 mM evoked on
the average, an increase in movement-evoked sensory activity
although individual responses in the same animal were rather
variable. As illustrated in the representative experiment of Fig. 2A
and B, the maximal increase in impulse activity (marked with a red
dot) usually occurred at the ﬁrst movement performed after BK
injection, but the effect of BK was in some cases less immediate and
the maximal rise in impulse frequency appeared during the second
movement [Fig. 2(A)]. For this reasonwe selected for the analysis ofTable I
Summary of the results for the different analysis performed in each experimental group.
column indicates the type of ﬁber identiﬁed in single units recordings. Values represent
Experimental groups % Of mean response
(95% CI)
% Of ﬁrs
(95% CI)
Group 1 BK Multiunit 152 (108e196) n ¼ 5 43 (16e
Single unit 109.5 (90.5e128.5) n ¼ 4 20 (3.5
Group 2 BKþ fasitibant Multiunit 95 (57e132) n ¼ 4 15.5 (
Single unit 79 (57e101) n ¼ 5 9 (20
Group 3 fasitibant Multiunit 101.4 (94e108) n ¼ 5
Single unit 104.8 (84e125) n ¼ 5
Group 4 saline Single unit 92 (56e128) n ¼ 4 4.75 (BK effects, the movement that evoked the highest frequency value
among the movements performed after injection of BK (marked
with a red dot in Fig. 2). On average, the increase of the mean
response to BK in multiunit recordings (152% (108e196) n ¼ 5) was
statistically signiﬁcant when compared with control movements
[100%; Figs. 2(A)e3(A), Table I; P ¼ 0.031, Paired t-test]. The ﬁrst
immediate response increased a 43% (16e70) and the average of
immediate responses a 46% (30e62) respect to control movements
[Fig. 3(BeC); Table I].
The fact that the average of the ﬁrst responses is similar to the
average of the repeated injections indicates a very limited tachy-
phylaxis, i.e., decrease in response caused by repeated doses of BK.
BK injection was also tested on seven single units in seven
different animals. In three of them, BK did not have any effect on
movement-evoked impulse response, suggesting that they were
insensitive to the drug (see supplementary data). Thus, they were
not included in the analysis of BK effects. In the remaining units, the
mean responses after repeated intra-arterial injection of 200 ml BK
100 mM did not reach signiﬁcant differences when was compared
with control [109.5% (90.5e128.5) n ¼ 4, Figs. 2(B)e3(A), Table I;
P ¼ 0.217, Paired t-test]. The ﬁrst immediate response was
augmented with respect to the movement activity prior BK in-
jections (20% (3.5 to 43.5)) as also occurred with the average of
the immediate responses [15.5% (0.5e30.5) Figs. 2(B), 3(BeC),
Table I].
To exclude a direct, unspeciﬁc stimulatory effect of the injection
itself, we tested the effect of an injection of saline on movement-
evoked activity, in single unit recordings. The mean responses after
repeated injection of saline alone [92% (56e128) n ¼ 4, Fig. 3(D),
Table I], was not signiﬁcantly different from control movements
(P ¼ 0.54, Paired t-test). We also found no signiﬁcant differences in
the ﬁrst immediate response (4.75% (16.5 to 7)) and in the
average of immediate responses (0.67% (5.5 to 4.2)) with respect
to the control movements (P ¼ 0.288 and P ¼ 0.68 respectively,
Paired t-test; Table I).
Effect of fasitibant on BK sensitization
Fig. 4 shows a representative example of the effect of fasitibant
on a multiunit nerve ﬁring recording of BK-sensitized movement-
evoked activity before (A) and after (B) close intra-arterial injection
of fasitibant. The impulse activity evoked by the injection of BK was
reduced when fasitibant was injected 30 s earlier, indicating that
the drug blocks the sensitizing effect of BK. The time course of this
type of experiment in multi- and single unit recordings is shown in
Fig. 2C and D. Previous injection of fasitibant (red arrows) consis-
tently reduced the number of movement-evoked impulses seen
under BK alone. The mean response in multiunit recordings
following BK plus fasitibant injectionwas 95% (57e132, n ¼ 4). This
activity was signiﬁcantly lower when compared with the equiva-
lent activity in animals that received intra-arterial injections of BK
but were not treated with fasitibant [152% (108e196) Fig. 3(A);The numbers of animals (n) used in each experimental group are indicated. The last
mean and 95% CI
t immediate response % Of average immediate response
(95% CI)
Type of ﬁbers
70) n ¼ 5 46 (30e62) n ¼ 5
to 43.5) n ¼ 4 15.5 (0.5e30.5) n ¼ 4 C4
30.3 to 0.7) n ¼ 4 7.3 (18.7 to 4) n ¼ 4
.5 to 2.5) n ¼ 5 16.7 (36.6 to 3.2) n ¼ 5 4C, 1Ad
4.3 (11 to 20) n ¼ 5
3.4 (9.1 to 2.3) n ¼ 5 2Ad, 3C
16.47 to 7) n ¼ 4 0.67 (5.5e4.2) n ¼ 4 3C
A. Gomis et al. / Osteoarthritis and Cartilage 21 (2013) 1346e1354 1351P ¼ 0.028, Student’s t-test]. In single unit recordings the averaged
activity in rats treated with fasitibant was also signiﬁcantly
lower (79% (57e101) n ¼ 5) than in non-treated animals [109.5%
(90.5e128.5) Fig. 3(A), Table I; P ¼ 0.022, Student’s t-test].
We also analyzed the ﬁrst immediate response after BK plus
fasitibant. This response was on average 15.5% (30.3 to 0.7)
and9% (20.5 to 2.5) with respect to control movements previous
the injections, in multi- and single unit recordings, respectively.
These decreases were statistically signiﬁcant compared to animals
not treated with fasitibant [Fig. 3(B); P ¼ 0.002 and P ¼ 0.008
respectively, Student’s t-test].
Finally, inhibition of BK sensitization by fasitibant was also
evident when we measured the mean value of the immediate re-
sponses after BK plus fasitibant treatment, in bothmulti- and single
unit experiments. A mean reduction of 7.3% (18.7 to 4) in
multiunit recordings and 16.7% (36.6 to 3.2) in single unit re-
cordings were measured. These decreases were statistically sig-
niﬁcant when compared with the increases in activity recorded
after BK injection alone [Fig. 3(C), Table I; P < 0.001 and P ¼ 0.01
respectively, Student’s t-test].
Direct effects of fasitibant
To rule out the possibility of a direct effect of fasitibant on knee
joint impulse responses to mechanical stimuli, we recorded the
nerve activity in non-inﬂamed knee joints after fasitibant injection,
in which BK levels are expectedly lower in comparison with
inﬂamed knee joints.
As shown in Fig. 3D, the mean response after intra-arterial
injection of fasitibant 300 mM alone was not statistically signiﬁ-
cant compared to control in multi- and in single unit recordings
(101.4% (94e108) n ¼ 5 and 104.8% (84e125), n ¼ 5; P ¼ 0.612 and
P ¼ 0.550 respectively, Paired t-test; Table I). Likewise, the ﬁrst
immediate responses after fasitibant were 4.3% (11 to 20) andFig. 5. Dose-dependent effect of the intra-articular administration of the kinin B2 recepto
comparison of intra-articular and intravenous antagonist administration route (D). Fasitibant
into the right knee joint. The knee joint incapacitation was measured at different times (x-a
mean values of right hind limb weight bearing as a percentage of total weight borne by both
#P < 0.05 vs the control group (one-way ANOVA followed by Dunnett post-test).3.4% (9.1 to 2.3) in multi- and single units respectively, and
were not different from the previous immediate movement (data
not shown; P ¼ 0.063 and P ¼ 0.181 respectively, Paired t-test;
Table I).
Effect of fasitibant on joint pain-associated behavior
In non-inﬂamed rats body weight distribution between the
two hind limbs was similar, whereas 6 h after carrageenan
administration, animals maintained only 24.4  4.1% of the
weight on the inﬂamed (right) hind limb, shifting the remaining
onto the contralateral leg. This value returned gradually to
control, increasing the weight on the treated limb to 30.3%
(28.2e32.5), 36.1% (32.4e39.8), 40.1% (38.3e41.9), and 42.2%
(39.0e44.8) of control at 1, 2, 3, and 4 days after carrageenan
injection, respectively, presumably reﬂecting a gradual decrease
in the joint pain [Fig. 5(A)], whereas no more differences could
be observed after 7 days from carrageenan treatment (data not
shown).
Intra-articular injection of fasitibant produced a dose-related
antinociceptive effect on the carrageenan-induced incapacitation.
Data obtained in animals treatedwith 10 mg of fasitibant (11.4 nmol/
rat) overlapped to those obtained with carrageenan injection alone
[Fig. 5(A)]. However, 30 mg (34.2 nmol/rat) fasitibant produced a
signiﬁcant antinociceptive effect both at 6 h and 1 day after
carrageenan treatment [Fig. 5(B)]. The antinociceptive effect of
fasitibant was greater and longer lasting in animals treated intra-
articularly with 100 mg (114 nmol/rat). At this dose, fasitibant
signiﬁcantly inhibited the carrageenan-induced incapacitation af-
ter 6 h and persisted up to 4 days after carrageenan treatment
[Fig. 5(C)]. No differences were observed between antagonist-
treated and vehicle-treated groups after 7 days after carrageenan
treatment, when nociceptive responsewere not more evident (data
not shown).r antagonist fasitibant on inﬂammatory pain in the time (6 he4 days) (A, B, C) and
was administered at different doses 30 min before carrageenan-induced inﬂammation
xis) from carrageenan administration (AeC) or 6 h later (D). Data points represent the
hind limbs. Error bars represent 95% CIs. *P < 0.05 vs the carrageenan-treated animals,
A. Gomis et al. / Osteoarthritis and Cartilage 21 (2013) 1346e13541352The effect of fasitibant administered intra-articularly or intra-
venously was compared at 6 h after carrageenan treatment. As
shown in Fig. 5D, contrary to the local treatment (intra-articular),
the intravenous fasitibant administration was ineffective in
decreasing the carrageenan-induced joint incapacitation.
Discussion
The present study aimed at deﬁning the contribution of kinin B2
receptors to inﬂammatory hyperalgesia and activation of sensory
afferent ﬁbers in the rat knee joint, as well as to ascertain the ef-
ﬁcacy of the kinin B2 receptor antagonist fasitibant in preventing
these phenomena. Previous reports indicated that intra-articular
application of BK into the rat knee joint increases the ﬁring rate
of its primary afferents, and that this sensitization appeared both in
normal and inﬂamed joints23,38. However, the blockade of these BK
effects by B2 receptor antagonists had not been explored so far. The
results of this study conﬁrm that in multiunits recordings of sen-
sory nerves innervating inﬂamed knee joints of rats, intra-articular
BK injection causes an acute and signiﬁcant increase of the impulse
ﬁring evoked by joint movements. Moreover, our work shows that
this stimulatory action of BK is still obtained after repeated in-
jections. In fact, the mean response to repeated BK injection is, on
the average, similar to the ﬁrst injection response, indicating that
desensitization did not play a critical role in our experimental
conditions. The average movement-evoked activity during the
complete time period of BK injections was signiﬁcantly higher than
during the control period, further suggesting that despite vari-
ability, BK had a sustained and long lasting sensitizing effect on
movement-evoked activity. The acute stimulatory effect of BK in-
jection on multiunit movement-evoked discharges was conﬁrmed
in single unit recordings, where an overall increase in impulse ac-
tivity during the period of repeated BK injections was also
observed, although the signiﬁcance levels obtained in multiunit
recordings were not reached. These results contrast with previous
observations made in the rat ankle joint39,40, where tachyphylaxis
induced by repeated intra-arterial injection of BK was reported.
Differences with our results could rely on the experimental model
used: non-inﬂamed joints in one case39 and joints inﬂamed with
Freund’s complete adjuvant injection in the other40. Furthermore,
in both studies, comparatively higher concentrations of BK (2e4
fold those employed in the current protocol) were used.
The main ﬁnding of the present work was that administration of
fasitibant prior to BK injection reduced the excitatory effects of BK,
including those evoked by repeated injections, thus leading to an
inhibition of the overall increase in movement-evoked activity
resulting of repeated exposure to BK. The effects of fasitibant were
observed both in multiunit and in single unit recordings. The
reduced movement-evoked activity in single units noticed after
injection of fasitibant plus BK could be attributed to a direct
inhibitory effect of the drug on movement-evoked impulse activity,
independent of its blocking action on BK effects. However, this
possibility can be excluded because repeated injections of fasitibant
into non-inﬂamed joints did not cause a signiﬁcant decrease of
movement-evoked activity. Therefore, the most likely explanation
to the reduction by fasitibant of impulse activity in inﬂamed in
contrast with non-inﬂamed knee joints, is that the drug not only
attenuated impulse discharge evoked by exogenous BK but also the
sensitizing effects on nerve endings of the endogenous BK released
in inﬂamed knee joints. In favor of this interpretation is the
observation that in the synovial lavage ﬂuid of carrageenan-treated
rats, the content of BK is higher when compared with controls32.
Thus, present ﬁndings indicate that B2 receptor blockade prevents
sensory neurons activation induced by BK, besides that induced by
the activation of proteinase-activated receptors41.We recently reported that fasitibant can partially block the
hyperalgesia and other inﬂammatory effects (after 6 h from carra-
geenan injection)32, and that different other mediators are
involved, such as leukotrienes, prostaglandins, and catechol-
amines33. In agreement with previous reports, B1 receptor activa-
tion was found to be involved in the carrageenan-induced
hyperalgesia, because this was partially inhibited by the B1 receptor
antagonist [DesArg9Leu8]-BK33. Furthermore, the present results
indicate that although fasitibant effectively blocked BK-induced
sensitization of joint afferents and decreased nociceptor ﬁring
rate consecutive to chemically induced joint inﬂammation, the
drug did not entirely eliminate hyperalgesia. This is in line with the
additional contribution of inﬂammatory agents other than BK to
the inﬂammation and sensitization developed in this model of
arthritis. In such context, it is worth pointing out that, with the
same experimental preparation, a combination of fasitibant with
the glucocorticoid dexamethasone completely reversed the signs of
both inﬂammation and hyperalgesia32.
The present data highlight the remarkable long duration of the
antinociceptive action of fasitibant, that at the highest concentra-
tion tested (100 mg/knee) reduced the carrageenan-induced
inﬂammatory hyperalgesia up to 4 days after antagonist adminis-
tration. This long lasting effect is in agreement with the pharma-
codynamic proﬁle of the drug. In fact, the slow dissociation proﬁle
of fasitibant from the B2 receptor compartment, and the docking
site of the drug, that is buried into the transmembrane portion of
the receptor protein42 can account for the long residence time of
the drug on the B2 receptor and explain the long duration of its
action in vivo43.
Finally, our data show that fasitibant antinociceptive effect was
obtained only with intra-articular injection whereas the intrave-
nous route was ineffective, indicating a local rather than systemic
action. This result is in line with previous observations in different
experimental models where fasitibant delivered by intratracheal
instillation or aerosol prevented bronchoconstriction and recruit-
ment of inﬂammatory cells but not the hypotension induced by
systemic administration of BK in anaesthetized guinea pigs29,44.
In conclusion, the present data show that fasitibant prevents B2
receptor-mediated activation and sensitization of joint nociceptors.
In spite of the limitations imposed by the differences between
animal models of joint pain and pain in human OA, this drug ap-
pears as a novel potential pharmacologic and symptomatic treat-
ment of pain in OA.
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